Nkarta, Inc. announced that Nadir Mahmood, PhD, has resigned his position as chief financial and business officer to serve as the chief executive officer of a private biotechnology company. Dr. Mahmood will remain with Nkarta until June 30, 2023, to ensure a smooth transition. Nkarta remains on track to announce updated results from its ongoing clinical trial of NKX101 in the second quarter of 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.01 USD | -3.53% | -8.94% | -8.94% |
Jun. 13 | Nkarta, Inc. Appoints George Vratsanos as Board of Directors | CI |
May. 25 | Certain Common Stock of Nkarta, Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2024. | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.94% | 424M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- NKTX Stock
- News Nkarta, Inc.
- Nkarta, Inc. Announces Resignation of Nadir Mahmood as Chief Financial and Business Officer